Breaking News Instant updates and real-time market news.

AAL

American Airlines

$37.78

0.91 (2.47%)

, PG

Procter & Gamble

$93.47

0.78 (0.84%)

07:35
11/14/18
11/14
07:35
11/14/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Tuesday in American Airlines (AAL), Procter & Gamble (PG), Las Vegas Sands (LVS), NIO Inc (NIO), Arconic (ARNC), MetLife (MET), Ralph Lauren (RL), Tenet (THC), USA Technologies (USAT), and Apptio (APTI).

AAL

American Airlines

$37.78

0.91 (2.47%)

PG

Procter & Gamble

$93.47

0.78 (0.84%)

LVS

Las Vegas Sands

$51.55

0.585 (1.15%)

NIO

NIO Inc.

$6.77

0.12 (1.80%)

ARNC

Arconic

$20.11

0.03 (0.15%)

MET

MetLife

$45.46

0.74 (1.65%)

RL

Ralph Lauren

$121.44

0.4 (0.33%)

THC

Tenet

$23.80

-1.92 (-7.47%)

USAT

USA Technologies

$4.71

-0.51 (-9.77%)

APTI

Apptio

$37.75

0.11 (0.29%)

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 03

    Mar

AAL American Airlines
$37.78

0.91 (2.47%)

10/30/18
JPMS
10/30/18
NO CHANGE
Target $46
JPMS
Overweight
American Airlines added to Analyst Focus List at JPMorgan
JPMorgan analyst Jamie Baker added American Airlines to his firm's Analyst Focus List. Baker this morning lowered his price target for the shares to $46 from $53 and kept an Overweight rating on the name.
10/17/18
DBAB
10/17/18
UPGRADE
Target $47
DBAB
Buy
American Airlines upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Michael Linenberg upgraded American Airlines Group to Buy and raised his price target for the shares to $47 from $40. The analyst cites the company's better than expected fuel expense for the upgrade.
10/17/18
10/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Infosys (INFY) upgraded to Market Perform from Underperform at William Blair WITH analyst Maggie Nolan citing Q2 results. 2. American Airlines (AAL), Delta Air Lines (DAL), and United Continental (UAL) upgraded to Buy from Hold at Deutsche Bank. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying based on trends associated with a number of its notable products, as well as his recent conversation with management, he believes a picture of sustainable EBITDA is emerging at Akorn that is better than what he had previously envisioned. 4. Workday (WDAY) upgraded to Outperform from Market Perform at Bernstein with analyst Mark Moerdler saying he determined that even if the ERP market moves reasonably slowly to the Cloud, it is large enough and the fact there are only a few vendors with a competitive SaaS solution should allow Workday to continue to gain share. 5. Domino's Pizza (DPZ) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson saying the pullback in the stock price is overdone and expects accelerated cost savings and solid comps to yield higher earnings, raising his FY20 EPS view to $12.01 from $11.72. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/18
GSCO
11/12/18
INITIATION
Target $44
GSCO
Buy
American Airlines initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Catherine O'Brien started American Airlines with a Buy rating and $44 price target. The analyst expects "idiosyncratic opportunities" to drive higher controllable earnings than the industry average. She also launched coverage on the U.S. Airlines sector with an Attractive coverage view. Stronger revenue trends in 2019 coupled with a focus on cost control should drive higher industry operating margins for the first time since 2015 despite fuel headwinds, O'Brien tells investors in a research note.
PG Procter & Gamble
$93.47

0.78 (0.84%)

10/22/18
WELS
10/22/18
NO CHANGE
Target $84
WELS
Market Perform
Procter & Gamble price target raised to $84 from $78 at Wells Fargo
Wells Fargo analyst Bonnie Herzog raised her price target for Procter & Gamble to $84 from $78 following quarterly results. Overall, the analyst thinks it remains a show-me story in the near-term with valuation appropriate considering where the company is in its turnaround process. Herzog reiterates a Market Perform rating on the shares.
10/19/18
JPMS
10/19/18
UPGRADE
JPMS
Overweight
Procter & Gamble upgraded to Overweight from Neutral at JPMorgan
10/22/18
RHCO
10/22/18
NO CHANGE
Target $85
RHCO
Hold
Procter & Gamble price target raised to $85 from $80 at SunTrust
SunTrust analyst William Chappell raised his price target on Procter & Gamble to $85 after its better than expected Q1 results / updated guidance but keeps his Hold rating, saying he prefers to see a "few more quarters of outperformance" before calling a "tipping point" for the company's investment story. The analyst further notes that Procter & Gamble was less impacted by the "negative headwinds of currency, commodities, tariffs, etc", as its organic growth rate also came in higher than anticipated, adding that the company has also become a "more focused business post its 2016 divestiture process".
10/19/18
JPMS
10/19/18
UPGRADE
Target $100
JPMS
Overweight
Procter & Gamble upgraded to Overweight with $100 target at JPMorgan
JPMorgan analyst Andrea Teixeira upgraded Procter & Gamble to Overweight from Neutral and raised her price target for the shares to $100 from $82. The stock in afternoon trading is up 8%, or $6.22, to $86.53 following this morning's Q1 results. The analyst sees an improved narrative on pricing and market share following this morning's report.
LVS Las Vegas Sands
$51.55

0.585 (1.15%)

10/19/18
10/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Las Vegas Sands (LVS) downgraded to Buy from Conviction Buy at Goldman Sachs. 2. eBay (EBAY) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying PayPal's (PYPL) earnings release last night suggested weak eBay gross merchandise volume trends in Q3. 3. Ford (F) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Adam Jonas saying he now believes the market needs more evidence of success before embracing the Ford restructuring story. 4. BNY Mellon (BK) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying while the company beat estimates this quarter, several line items were weaker than expectations. 5. Harley-Davidson (HOG) downgraded to Market Perform from Outperform at BMO Capital with analyst Gerrick Johnson saying his previously expected catalysts for sales and earnings did not materialize. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/18
ROTH
11/08/18
NO CHANGE
Target $140
ROTH
Buy
Wynn Resorts price target lowered to $140 from $210 at Roth Capital
Roth Capital analyst David Bain lowered his price target for Wynn Resorts (WYNN) to $140 from $210 as he believes Q4 Macau EBITDA guidance of between $304M-$340M versus $400M consensus exposes VIP/high-end play volatility in Macau and downside risks in the current China economy. While Wynn is the most exposed to VIP weakness in Macau, the analyst believes commentary stops the small momentum other Macau names were beginning to build since Las Vegas Sands (LVS) and MGM Resorts (MGM) reported earnings. He reiterates a Buy rating on Wynn's shares.
10/25/18
DBAB
10/25/18
NO CHANGE
Target $63
DBAB
Hold
Las Vegas Sands price target lowered to $63 from $75 at Deutsche Bank
Deutsche Bank analyst Carlo Santarelli lowered his price target for Las Vegas Sands to $63 citing lower target multiples and modestly lower growth expectations following the company's Q3 results. The analyst, however, sees "limited causes for concern" in the Macau results. He believes the stock will be "broadly range-bound here" and keeps a Hold rating on Las Vegas Sands.
10/25/18
STFL
10/25/18
NO CHANGE
Target $72
STFL
Buy
Las Vegas Sands tone on Macau trends encouraging, says Stifel
Stifel analyst Steven Wieczynski said he would expect Las Vegas Sands shares to trade higher in response to the company's Q3 report in a normal world, noting that not only were the results better than feared but management's tone around current Macau business trends "could not have been more encouraging." He also contends that Las Vegas Sands' upsized Macau reinvestment capital budget gives a signal on management's belief regarding the path forward in Macau. However, he prefers to take "an ultra-conservative approach" to the Macau market "for the time being" and lowered his price target to $72 from $86, though he adds that he believes his revised estimates will ultimately prove to be conservative. Wieczynski keeps a Buy rating on Las Vegas Sands shares.
NIO NIO Inc.
$6.77

0.12 (1.80%)

10/09/18
10/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Macquarie. 2. Tellurian (TELL) initiated with a Buy at BofA/Merrill. 3. NIO Inc. (NIO) initiated with a Neutral at JPMorgan and an Overweight at Morgan Stanley. 4. Eyenovia (EYEN) initiated with a Buy at H.C. Wainwright. 5. Garrett Motion (GTX) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/18
MSCO
10/09/18
INITIATION
Target $8.5
MSCO
Overweight
NIO Inc. initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jack Yeung initiated NIO Inc. with an Overweight rating and $8.50 price target, projecting a sales volume CAGR of 54.5% in 2017-22 for China's premium EV market and contending that NIO's price advantage over foreign competitors will allow it to penetrate the market. He notes that NIO's ES8, the company's first mass-produced model, has best-in-class specifications but a lower price, partly due to local manufacturing subsidies, the absence of customs duties and reduced taxes.
10/22/18
FBCO
10/22/18
INITIATION
Target $12.6
FBCO
Outperform
Credit Suisse starts NIO Inc. with an Outperform rating, $12.60 price target
Credit Suisse analyst Bin Wang initated NIO Inc. with an Outperform rating and $12.60 price target, stating that the company has a well-establish premium branding in China and is a leader in smart electric vehicle technology. He estimates NIO's revenue will grow at a 192% CAGR to 2020 and sees the company achieving its first year of breakeven in 2021, when Wang assumes it will be able to produce 165,000 units.Target $12.60.
11/06/18
SBSH
11/06/18
NO CHANGE
Target $7.2
SBSH
Neutral
Citi sees three catalysts in three months for shares of NIO
Citi analyst Jeff Chung views NIO Inc.'s Q3 results as generally in-line with consensus and says its Q4 revenue only needs to achieve 70% quarter-over-quarter growth in order to meet his fiscal 2018 forecast, which he believes "carries very high visibility now." The analyst sees three catalysts for the shares in the next months. The first being December ES8 sales and production run-rate accelerating to 30,000 units from November's 23,000-25,000 units. The second being NIO announcing ES6 order backlog status between the end of fiscal 2018 and January 2019. And the third being the company's Q4 earnings report in February 2019. In a best case scenario, Chung expects Q4 revenue up 85% to 110% quarter-over-quarter. He keeps a Neutral rating on NIO Inc. with a $7.20 price target.
ARNC Arconic
$20.11

0.03 (0.15%)

09/17/18
LBOW
09/17/18
DOWNGRADE
LBOW
Neutral
Arconic downgraded to Neutral from Buy at Longbow
09/17/18
09/17/18
DOWNGRADE

Neutral
Arconic downgraded to Neutral on valuation at Longbow
As previously reported, Longbow downgraded Arconic to Neutral from Buy. Analyst Chris Olin cites valuation, limited upside to EP&S Segment margins and recent checks that appear evenly balanced for his change in view.
10/10/18
MSCO
10/10/18
NO CHANGE
Target $22
MSCO
Equal Weight
Morgan Stanley says Arconic could rise to $28, or fall to $17, pending review
With Arconic expected to host an investor event in November where management is expected to share the results of their strategic review, Morgan Stanley analyst Rajeev Lalwani lays out three potential scenarios and the associated move in the stock that he sees in each theoretical case. In Scenario 1, which he views as most probable, Arconic will announce significant asset sales as it continues its shift toward becoming a pure-play A&D company. In such a scenario, Lalwani sees the stock trading at about $22 per share. In Scenario 2, the company announces a full buyout and he sees the stock moving up to about $28 per share. Lalwani puts the odds of this scenario at 30%. In Scenario 3, the company announces limited strategic activity beyond those noted to-date and in such a case Lalwani sees the stock falling to $17 per share to re-test its early 2018 lows. Ahead of the potential catalyst of the investor day and end of the review, Lalwani keeps an Equal Weight rating and $22 price target on Arconic.
10/31/18
JEFF
10/31/18
NO CHANGE
Target $25
JEFF
Buy
Arconic risk/reward favorable after Q3 beat, says Jefferies
Jefferies analyst Martin Englert reiterates a Buy rating on Arconic with a $25 price target citing a favorable risk/reward post the company's Q3 beat and reports of a possible private equity takeout. The company continues to make incremental improvements within Engineered Products & Solutions amidst partly offsetting factors, Englert tells investors in a post-earnings research note. He notes that his leveraged buyout model values Arconic at $26 per share.
MET MetLife
$45.46

0.74 (1.65%)

03/26/18
03/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) and Analog Devices (ADI) upgraded to Outperform from Market Perform at Raymond James. 2. D.R. Horton (DHI) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying he sees the company as well positioned to absorb volume demand while maintaining gross margins. 3. RBS (RBS) upgraded to Buy from Hold at Deutsche Bank with the firm saying the recent underperformance of shares has brought an attractive entry point. 4. MetLife (MET) upgraded to Overweight from Neutral at Atlantic Equities. 5. Dollar Tree (DLTR) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying he believes the company is making "sensible investments" with Family Dollar to drive comp growth improvement into 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
FBCO
04/25/18
INITIATION
Target $67
FBCO
Outperform
MetLife initiated with an Outperform at Credit Suisse
Credit Suisse analyst Andrew Kligerman started MetLife with an Outperform rating and $67 price target as he believes its low valuation appears not to reflect the less equity-sensitive nature of its strong remaining businesses and likely a 12% ROE by 2020, supported by organic growth, capital management, and sizable cost savings.
06/04/18
06/04/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Big Lots (BIG) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba saying the company got off to a "tough start in fiscal 2018 with a store sales decline and continued slowdown in furniture sales." 2. Jounce Therapeutics (JNCE) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying he views the company's ASCO data as disappointing. 3. MetLife (MET) downgraded to Neutral from Buy at Goldman Sachs with analyst Alex Scott saying he see slower progress towards return on equity improvement and believes some of the upside from capital return acceleration is behind the company at this point. 4. Dollar Tree (DLTR) downgraded to Accumulate from Buy at Gordon Haskett. 5. SM Energy (SM) downgraded to Neutral from Outperform at Credit Suisse with analyst Betty Jiang saying she believes SM Energy's discount valuation is appropriate given it has greater than average downside risk in a constrained Permian takeaway environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/04/18
GSCO
06/04/18
DOWNGRADE
Target $52
GSCO
Neutral
MetLife downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Alex Scott downgraded MetLife to Neutral and lowered his price target for the shares to $52 from $54. The analyst see slower progress towards return on equity improvement and believes some of the upside from capital return acceleration is behind the company at this point.
RL Ralph Lauren
$121.44

0.4 (0.33%)

11/06/18
JPMS
11/06/18
NO CHANGE
JPMS
Ralph Lauren weakness a buying opportunity, says JPMorgan
11/07/18
UBSW
11/07/18
NO CHANGE
Target $112
UBSW
Sell
Ralph Lauren expectations still look too high, says UBS
UBS analyst Jay Sole views Ralph Lauren as a turnaround stock, but he believes the company lacks the core brand strength needed to achieve the Street's targets. The analyst said comps get tougher in 2020, which he believes will lead to downward earnings revisions. Sole reiterated his Sell rating and $112 price target on Ralph Lauren shares.
10/29/18
DBAB
10/29/18
INITIATION
Target $149
DBAB
Buy
Ralph Lauren initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Paul Trussell started Ralph Lauren with a Buy rating and $149 price target. The analyst believes the brand's turnaround is in the early stages and views current share levels as proving a favorable entry point.
10/29/18
10/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with a Buy at Jefferies. 2. Ralph Lauren (RL) initiated with a Buy at Deutsche Bank. 3. Guardant Health (GH) initiated with an Outperform at Cowen and William Blair, an Overweight at JPMorgan, and a Neutral at BofA/Merrill. 4. Kodiak Sciences (KOD) initiated with a Buy at BofA/Merrill, as well as an Overweight at Barclays and Morgan Stanley. 5. Proteostasis (PTI) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
THC Tenet
$23.80

-1.92 (-7.47%)

08/14/18
LEHM
08/14/18
INITIATION
LEHM
Barclays starts Hospital sector with Neutral outlook, top pick HCA
Barclays analyst Steve Valiquette initiated coverage of the Hospital sector with a Neutral rating. Operators continue to face incremental pressures from alternative payment models that are shifting incentives towards lower-cost sites of care, Valiquette tells investors in a research note. He believes, however, that despite industry headwinds, operators levered to markets with high population growth and high relative market share will continue to outperform the industry. The analyst's only Overweight rated name in space is HCA Healthcare (HCA). The analyst initiated coverage of HCA with an Overweight rating and $150 price target. He sees HCA as well positioned in local markets. Valiquette also started Universal Health Services (UHS) and Tenet Healthcare (THC) with Equal Weight ratings. His lone Underweight rating is put on Community Health Systems (CYH). The company is still burdened with excessive debt and constrained free cash flow from its rural hospital footprint, Valiquette contends.
08/14/18
LEHM
08/14/18
INITIATION
Target $35
LEHM
Equal Weight
Tenet initiated with an Equal Weight at Barclays
Barclays analyst Steven Valiquette started Tenet Healthcare with an Equal Weight rating and $35 price target.
08/08/18
MZHO
08/08/18
NO CHANGE
Target $36
MZHO
Buy
Tenet post-earnings selloff seems overdone, says Mizuho
Mizuho analyst Ann Hynes believes the post-earnings selloff yesterday in shares of Tenet Healthcare seems overdone. The Q2 earnings report shows Tenet has initiatives underway that should improve its earnings, margin and cash flow profile, Hynes tells investors in a research note. The analyst raised her price target for the shares to $36 from $35 and keeps a Buy rating on Tenet.
11/07/18
MSCO
11/07/18
NO CHANGE
MSCO
Split Congress 'best outcome' for MCOs and hospitals, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak contends that the Democratic party retaking the majority in the House of Representatives and Republicans retaining the Senate is the "best outcome" for Managed Care Organizations and hospitals, stating that he now sees another attempt at a repeal/replace of the Affordable Care Act as "off the table." The split Congress could also lower the volume on the "Medicare for All" debate given a lack of mandate from either the Democratic or Republican party, Sopcak tells investors. The election results remove a key overhang for Centene (CNC) and Molina (MOH), which he views as most exposed to the ACA marketplace, and to a lesser extent the hospitals, Sopcak added. With ACA repeal/replace off the table, and given the longer term potential upside from Medicaid expansion in Utah and Idaho as expansion ballot initiatives appear to be passing in both states, Sopcak said Molina is emerging as his top pick in the space heading into the final weeks of 2018. Publicly traded hospital companies include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
USAT USA Technologies
$4.71

-0.51 (-9.77%)

06/13/18
LSCM
06/13/18
NO CHANGE
Target $17
LSCM
Buy
USA Technologies price target raised to $17 from $11 at Lake Street
Lake Street analyst Jaeson Schmidt raised his price target for USA Technologies to $17 after taking over coverage of the name. USA Technologies is the "dominant player in a rapidly growing market," Schmidt tells investors in a research note. He believes the company can post "meaningful top and bottom line growth" as it benefits from continued adoption in the connected vending space, further penetration in adjacent markets such as kiosks and self-check-outs, and the ability to drive improving leverage. The analyst reiterate s a Buy rating on the shares.
04/03/18
LSCM
04/03/18
INITIATION
Target $11
LSCM
Buy
USA Technologies initiated with a Buy at Lake Street
Lake Street analyst Josh Elving started USA Technologies with a Buy rating and $11 price target. The analyst believes believe most, if not all, vending machines will offer cashless acceptance in the near-term. He views USA Technologies as the leader in providing cashless and contactless payment solutions to the vending industry.
04/03/18
04/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. LogMeln (LOGM) initiated with a Buy at Mizuho. 2. Jones Lang LaSalle (JLL) initiated with a Neutral at Goldman Sachs. 3. Spotify (SPOT) initiated with a Buy at Guggenheim. 4. USA Technologies (USAT) initiated with a Buy at Lake Street. 5. Stryker (SYK) initiated with an In Line at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/18
BRRR
10/01/18
NO CHANGE
BRRR
Barrington suspends USA Technologies rating on annual filing delay
Barrington analyst Gary Prestopino temporarily suspended his investment rating on USA Technologies citing the continuing delay in issuing its fiscal 2018 annual report "coupled with a lack of ability to provide any transparency into the issues revolving around its inability to issue" the report. The analyst says he will re-evaluate his investment rating once the company reports its Q4 and fiscal 2018 financial results.
APTI Apptio
$37.75

0.11 (0.29%)

09/13/18
JEFF
09/13/18
NO CHANGE
Target $47
JEFF
Buy
Apptio price target raised to $47 from $44 at Jefferies
Jefferies analyst John DiFucci raised his price target for Apptio to $47 after hosting an investor meeting with management. The company is well positioned with its current product portfolio to sustainably grow subscription revenue 20% and to show modest operating margin leverage in the near to medium term, DiFucci tells investors in a research note. He maintains a Buy rating on shares of Apptio.
10/30/18
RBCM
10/30/18
NO CHANGE
Target $35
RBCM
Outperform
Apptio price target lowered to $35 from $42 at RBC Capital
RBC Capital analyst Ross MacMillan lowered his price target on Apptio to $35 after its "noisy" Q3 results that featured a "subscription revenue sequential deceleration" and billings growth of over 20%. The analyst also keeps his Outperform rating but reduces his 2019 revenue growth estimate from high to mid teens and also lowers his implied valuation target multiple to 5-times from 6-times.
10/30/18
JEFF
10/30/18
NO CHANGE
Target $40
JEFF
Buy
Apptio earnings selloff brings 'compelling' opportunity, says Jefferies
Apptio modestly exceeded Q3 expectations, guided Q4 about in line and raised its fiscal 2018 guidance by more than the modest Q3 beat, Jefferies analyst John DiFucci tells investors in a research note. The analyst views the outlook as "very attainable" and remains "encouraged" by management's execution "on numerous fronts." The post-earnings selloff represents a "compelling opportunity," DiFucci says. He lowered his price target for Apptio to $40 from $47 and maintains a Buy rating on the shares.
11/12/18
JEFF
11/12/18
NO CHANGE
Target $40
JEFF
Buy
Jefferies sees 'slight potential' for competing Apptio bid
Jefferies analyst John DiFucci thinks the 53% premium paid by Vista for Apptio (APTI) is a "fair deal." However, the analyst thinks there is "slight potential" for other interested parties to weigh in. The deal includes a 30 day go-shop period, which permits Apptio's board and advisors to actively solicit other deals, DiFucci tells investors in a research note. The analyst keeps a Buy rating on the shares with a $50 price target.

TODAY'S FREE FLY STORIES

ENLAY

Enel

$0.00

(0.00%)

05:32
09/20/19
09/20
05:32
09/20/19
05:32
Upgrade
Enel rating change  »

Enel upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$36.17

-1.075 (-2.89%)

05:31
09/20/19
09/20
05:31
09/20/19
05:31
Downgrade
Synovus rating change  »

Synovus downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

W

Wayfair

$128.67

-3.065 (-2.33%)

05:29
09/20/19
09/20
05:29
09/20/19
05:29
Initiation
Wayfair initiated  »

Wayfair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYL

Xylem

$77.99

-0.41 (-0.52%)

05:29
09/20/19
09/20
05:29
09/20/19
05:29
Initiation
Xylem initiated  »

Xylem initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 31

    Oct

PRDSY

Prada

$0.00

(0.00%)

05:28
09/20/19
09/20
05:28
09/20/19
05:28
Downgrade
Prada rating change  »

Prada downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURBY

Burberry

$0.00

(0.00%)

05:27
09/20/19
09/20
05:27
09/20/19
05:27
Upgrade
Burberry rating change  »

Burberry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

05:26
09/20/19
09/20
05:26
09/20/19
05:26
Upgrade
J Sainsbury rating change  »

J Sainsbury upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$10.45

0.095 (0.92%)

05:25
09/20/19
09/20
05:25
09/20/19
05:25
Initiation
Freeport McMoRan initiated  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

ANFGY

Antofagasta

$0.00

(0.00%)

05:23
09/20/19
09/20
05:23
09/20/19
05:23
Downgrade
Antofagasta rating change  »

Antofagasta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRC

AtriCure

$26.02

0.22 (0.85%)

05:21
09/20/19
09/20
05:21
09/20/19
05:21
Recommendations
AtriCure analyst commentary  »

AtriCure one of the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$10.50

-0.54 (-4.89%)

05:19
09/20/19
09/20
05:19
09/20/19
05:19
Recommendations
Neuronetics analyst commentary  »

Piper calls Neuronetics a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FGEN

FibroGen

$39.69

-1.3 (-3.17%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

05:16
09/20/19
09/20
05:16
09/20/19
05:16
Hot Stocks
FibroGen, Astellas Pharma announce Japanese approval of Evrenzo »

FibroGen (FGEN) and…

FGEN

FibroGen

$39.69

-1.3 (-3.17%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

VOPKY

Koninklijke Vopak

$0.00

(0.00%)

05:16
09/20/19
09/20
05:16
09/20/19
05:16
Upgrade
Koninklijke Vopak rating change  »

Koninklijke Vopak…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYA

Liberty Global

$27.09

-0.25 (-0.91%)

05:12
09/20/19
09/20
05:12
09/20/19
05:12
Downgrade
Liberty Global rating change  »

Liberty Global downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 07

    Nov

HRI

Herc Holdings

$45.32

-1.615 (-3.44%)

, URI

United Rentals

$125.06

0.415 (0.33%)

05:06
09/20/19
09/20
05:06
09/20/19
05:06
Upgrade
Herc Holdings, United Rentals rating change  »

Herc Holdings upgraded to…

HRI

Herc Holdings

$45.32

-1.615 (-3.44%)

URI

United Rentals

$125.06

0.415 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

URI

United Rentals

$125.06

0.415 (0.33%)

05:03
09/20/19
09/20
05:03
09/20/19
05:03
Upgrade
United Rentals rating change  »

United Rentals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SUZ

Suzano

$15.97

-0.43 (-2.62%)

04:59
09/20/19
09/20
04:59
09/20/19
04:59
Downgrade
Suzano rating change  »

Suzano downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$133.76

3.97 (3.06%)

, CMCSA

Comcast

$46.68

-0.25 (-0.53%)

04:56
09/20/19
09/20
04:56
09/20/19
04:56
Initiation
Pivotal starts 'dramatically overvalued' Roku with Sell rating, $60 target »

Pivotal Research analyst…

ROKU

Roku

$133.76

3.97 (3.06%)

CMCSA

Comcast

$46.68

-0.25 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

FTCH

Farfetch

$8.91

-0.42 (-4.50%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Cowen retail/luxury analyst to hold an analyst/industry conference call »

Retail & Luxury Goods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FB

Facebook

$190.15

1.96 (1.04%)

, SNAP

Snap

$16.87

-0.04 (-0.24%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

technology and Internet…

FB

Facebook

$190.15

1.96 (1.04%)

SNAP

Snap

$16.87

-0.04 (-0.24%)

TWTR

Twitter

$42.94

-0.29 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

TRGP

Targa Resources

$40.89

-0.725 (-1.74%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Targa Resources management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

IRM

Iron Mountain

$32.15

-0.02 (-0.06%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Iron Mountain management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

LGND

Ligand

$104.62

5.37 (5.41%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Ligand management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 02

    Oct

  • 13

    Nov

RDFN

Redfin

$17.19

-0.62 (-3.48%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Redfin management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

EXPI

eXp World Holdings

$8.45

0.33 (4.06%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
eXp World Holdings management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 07

    Oct

  • 08

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.